Virtual Challenging Case Clinic: Multiple Myeloma Updates from ASH and Year in Review

 

Release Date: January 29, 2021
Expiration Date: January 29, 2022

Target Audience

This activity is for clinicians who treat patients with multiple myeloma (hematologists, medical oncologists, oncology nurses and nurse practitioners, oncology pharmacists). 
 
Learning Objectives
After completing this activity, participants should be better able to:
  • Evaluate best available evidence regarding the treatment of patients with multiple myeloma
  • Assess the implications of emerging clinical trial data regarding multiple myeloma treatment approaches
  • Develop strategies to address complicated multiple myeloma cases

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Disclosure Declaration

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations. 
 
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.


Faculty Disclosures
All faculty and planning committee members have no conflicts to disclose with the exception of the following:


Course Director
Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing


Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Support
This activity is supported by independent educational grants from Bristol Myers Squibb, GlaxoSmithKline LLC, and Oncopeptides.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.